Select a medication above to begin.
Spherusol
coccidioides immitis spherule-derived skin test antigen
Black Box Warnings .
Administration
coccidioides immitis spherule-derived skin test antigen should never be given intravenously
Expected Response
local inflammation at skin test site expected; dime to quarter size rxn reaching max diameter at 24-48h; larger accelerated rxn can occur, may require tx w/ local cold compresses and anti-inflammatory medication
Systemic Reactions
can occur w/ skin test antigens; may be life-threatening or cause death in certain patients; emergency measures w/ trained personnel should be immediately avail; observe patients for at least 20min following skin test admin.
Report Adverse Reactions
contact Nielsen BioSciences, Inc. at 855-855-1212 or MedWatch, FDA 5600 Fishers Lane, Rockville, MD 20852, 800-332-1088, www.vaers.hhs.gov
Adult Dosing .
Dosage forms: INJ
delayed-type hypersensitivity detection, Coccidioides immitis
- [<65 yo]
- Dose: 0.1 mL intradermally x1 dose; Info: for patients w/ pulmonary coccidioidomycosis history; assess injection site induration 44-52h after admin; positive response = greater than 5 mm mean induration area orthogonal diameters
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.